LK 002
Alternative Names: LK-002Latest Information Update: 31 Mar 2025
At a glance
- Originator LiveKidney.Bio
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Kidney disorders; Lupus nephritis
Most Recent Events
- 28 Mar 2025 Clinical trials in Kidney disorders (Parenteral) prior to March 2025 (Livekidney.bio Pipeline, March 2025)
- 28 Mar 2025 Clinical trials in Lupus nephritis (Parenteral) prior to March 2025 (Livekidney.bio Pipeline, March 2025)
- 20 Jun 2023 LiveKidney.Bio files for patent protection for 'Hydrogel compositions containing cellular products'